
GI oncologist @HenryFordHealth with a focus on #pancreaticcancer; optimistic realist; wife, mother, fellow human. Opinions are my own.
Detroit, MI
Joined September 2009
- Tweets426
- Following932
- Followers591
- Likes1.1K
Today, the U.S. Food and Drug Administration (FDA) announced that it has issued a “safe to proceed” letter to @RevMedicines, allowing the company to initiate an expanded access treatment protocol (EAP) for daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). 💊
Expanded access is a potential pathway for patients with serious or life-threatening conditions to gain access to investigational medicines outside of a clinical trial when they are unable to participate in a clinical trial and all other appropriate treatment options have been exhausted.
In response to the FDA’s letter, Revolution Medicines said that this “represents a critical step in the process of opening an EAP” and that they are “moving as quickly as possible to ensure safe and equitable access to daraxonrasib for eligible patients in the United States,” according to a statement from the company.
Read Revolution Medicines’ Expanded Access Policy, including how to submit a request through a licensed treating physician and how daraxonrasib is extending survival for #pancreaticcancer patients at 🔗 pcan.at/rjul9sza.
Maria Diab retweeted
Final Call! The CME/CE-accredited Detroit 2026 Hematology and Oncology Practice Symposium is just around the corner! Led by Drs. @FawziAbuRous and @MariaDiab101 , this interactive symposium will deliver practice-changing insights across lung, GI, GU, breast, and hematologic cancers—along with a keynote on the evolving role of antibody-drug conjugates. Register NOW: binaytara.org/projects/confe… #CMEConference #Oncology #Hematology #CancerCare #Binaytara #HemOnc #MedTwiiter #MedX
Maria Diab retweeted
Just activated!
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal
adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice
SOC w/wo panitumumab.
PI: Rachael A. Safyan, MD @fredhutch
swog.org/clinical-trials/S24…
Maria Diab retweeted
Last chance to register! Join @FawziAbuRous, @MariaDiab101, and other leading #oncology experts from @HenryFordHealth, @karmanoscancer, @UMRogelCancer, @umichmedicine @UMichRadOnc, @IHACares and @CorewellHealth at the CME/MOC-accredited #DetroitHemOnc25 in #Detroit! Register NOW: education.binayfoundation.or…
#HemOnc #MedEd #MedX #MedTwitter
Maria Diab retweeted
Came across @ShaalanBeg & @cancerassassin1 having a heated debate at #ASCO24
An Annual Meeting classic 🫡
Maria Diab retweeted
Preprint from @HenryFordHealth #PancreaticCancer research team (@HCCvPDAC @Daniel_Salas671 @NinaSteele17) + @DelgiornoKathy @SearsRosie
Metaplastic tuft cells transdifferentiate to neural-like progenitor cells in the progression of #PancreaticCancer
biorxiv.org/content/10.1101/…
Mostly curious how long this took(😱):
Ptf1aFlpO/+; FSF-KRASG12D/+; Trp53Frt-Exons 2 to 5-Frt/+; Pou2f3CreERT/+; ROSA26LSL-TdTomato/+, a.k.a. “KPF-P2f3T” mice.
biorxiv.org/content/10.1101/…
Maria Diab retweeted
The 5-year survival rate for #pancreaticcancer has increased to 13%, according to the American Cancer Society’s Cancer Facts & Figures 2024 Report, released today. 💜
This statistic has increased three years in a row — a promising trend that points to continued progress for pancreatic cancer patients. There is more hope than ever before, but there is still more work to be done.
We remain committed to our long-standing research priorities: To find an early detection strategy and accelerate treatments for patients with pancreatic cancer. We’re on the right path to achieve our bold goal of reaching a five-year survival rate of 20% by 2030. Together, we can make it happen. 💪
Learn more about what this means for patients at: pcan.at/a25jq7.
Maria Diab retweeted
A recording of Dr. @KimmieNgMD's #GI24 keynote lecture is now available, "The Growing Problem of Early-Onset Gastrointestinal Cancers."
Watch here ➡️ brnw.ch/21wGg4Z #gicsm #OncTwitter
Maria Diab retweeted
With an armamentarium of drugs with different MOAs, how should we sequence therapies for advanced #HepatocellularCarcinoma? @MariaDiab101 & Dr. Philip A. Philip discuss: fal.cn/3wZfX #gicsm #ASCODailyNews
Maria Diab retweeted
Every New Year's Eve I take the grim but necessary inventory of the patients I've lost
As a GI oncologist I've watched more than 60 -- more than 1 a week -- dear people succumb to their illness in 2022
They will not be forgotten
We must do better
And there is real hope we can
Very useful pearls regarding the fellowship match.
I’ve spent time thinking about the fellowship match & I’ve interviewed applicants since joining faculty
Here's a 🧵about the fellowship match
@WinshipAtEmory #MedTwitter
1/
1
Maria Diab retweeted
Tune in early
Tomorrow for the fabulous Dr Alese #gicancer
Winship #GrandRounds Webinar - August 17
Olatunji Alese, MD | Winship Cancer Institute of Emory University
"Role of Expanding Molecular Targets in Personalized GI Cancer Treatment"
➡️ fal.cn/3r4KN
Maria Diab retweeted
SO HAPPY to share this GREAT news co-led by @adasarimd! 🙏💙 to all of the patients!
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer globenewswire.com/news-relea… @VUMChealth @VUMCHemOnc @VUMC_Cancer
Proud of my hubby and of all @WomenInMedicine
Had the honor to do the last liver transplant with these two graduating @womeninsurgery. This is a first at Emory. Good luck on your future endeavors. Arielle Cimeno, MD @uchicagosurgery & Sharon Yu, MD @PiedmontHealth. @EmoryUniversity @EmorySurgery @emoryhealthcare @ASTSChimera
2
Maria Diab retweeted
Closing out day two at #DDHO2022 with a panel discussion featuring our line-up of GI cancer experts.
Maria Diab retweeted
Tune in to hear @MariaDiab101 and Dr. Olumide Gbolahan debate whether ctDNA should be used to guide adjuvant therapy in colorectal cancer at #DDHO2022
Maria Diab retweeted
Thanks @letswinpc for featuring our trial of IL6/PD1 blockade in #pancreaticcancer @WinshipAtEmory > 7 yr of preclinical work to get here. Cheers to @TMaceLab @BasselElRayesMD @MariaDiab101 +many others for making it happen. Hope to help patients and learn about stroma/immunity
Could a novel combination of monoclonal antibodies block abnormal cell growth and restore antitumor activity? Researchers are looking at a combination of two types of monoclonal antibodies to treat advanced pancreatic cancer. letswinpc.org/clinical-trial…
Maria Diab retweeted
We hope you will join us – either at Sea Island, or virtually – and look forward to your participation at #DDHO22!
Register today at loom.ly/E79_-ok, and join chair @SagarLonialMD of @WinshipAtEmory on July 21-24! #hematology #oncology




























